Fig. 3.

EMG outcomes assessed in Patient 2 up to 12 months after systemic–intraosseous DT-DEC01 administration. EMG assessment of average MUP duration revealed significant increase: A in the deltoideus by 33.6 ± 9.3%, B in the biceps brachii 149.6 ± 19.3%, C in the rectus femoris by 63.5 ± 7.8% and D in the gastrocnemius by 33.2 ± 7.6% compared to baseline. The data are expressed as mean ± SEM, and the average of 10 MUP measurements is shown. The statistical significance was assessed by Kruskal–Wallis test, with *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 denoting significant differences. V0a screening visit, V5 3-month, V6 6-months, V7 12-month visit after DT-DEC01 administration